



1121 Walkers Line, Suite 3, Burlington, ON CANADA L7N 2G4 Tel.: (416) 477-1052 info@rapid-dose.com www.rapid-dose.com

Rapid Dose Therapeutics Inc. Extends Scientific Research Agreement with McMaster University, Hamilton, Ontario, Canada

Burlington, Canada, August 1, 2018 – Rapid Dose Therapeutics Inc. (“RDT” or the “Corporation”) is pleased to announce that the Corporation is continuing to further the scientific research agreement with McMaster University, Hamilton, Ontario, Canada. The scientific research is being conducted by the Adronov Research Group of the Department of Chemistry and Chemical Biology. The Principal Investigator is Dr. Alex Adronov, the 2018 winner of the Chemical Institute of Canada’s Macromolecular Science and Engineering Award.

Dr. Adronov won the Macromolecular Science and Engineering Award for his pioneering work in the synthesis of complex polymers with controlled architectures and well-defined reactivity as well as for his investigations of the interactions between conjugated polymers and single-walled carbon nanotubes. Over the course of his career, Dr. Adronov has established himself as a national leader in the multi-step preparation of novel polymers and has published over 100 scientific articles in peer-reviewed journals. The 2018 award follows Dr. Adronov’s award for Excellence in Materials Chemistry, which he received from the Chemical Institute of Canada in 2013.

The Adronov Group, introduced to the project in 2017, has been studying the basis of RDT’s QuickStrip™ technology as a water-soluble polymer strip designed for transmucosal drug delivery suitable for delivering a wide range of active ingredients, while maintaining favourable dissolution parameters and consistent drug-loading characteristics.

Rapid Dose Therapeutics Inc. CEO Mr. Mark Upsdell noted, “The work for which the Adronov Group is known is ideal for the rapid advancement of RDT’s products into multiple market segments of our target verticals. The Adronov Group has expertise in polymers utilizing nano-scale dispersions, as well as the chemical stability of emulsions and nanocomposites which figure greatly into our goal of further innovating stable dispersions within a polymer film.”

The end result of the continuing research by the Adronov Group will allow RDT to critically evaluate many more pharmaceutical and nutraceutical products for QuickStrip™ oral sublingual delivery, which could dramatically expand RDT’s global market presence.

About Rapid Dose Therapeutics Inc.

Rapid Dose Therapeutics Inc. is a Canadian biotechnology corporation providing disruptive proprietary drug delivery technologies designed to improve patient outcomes. The Company manufactures, distributes, and licenses its orally administrable composition of a film forming agent that delivers a micronized therapeutic to allow the ready absorption of pharmaceutical and other products to patients.

For more information, visit: rapid-dose.com

For media inquiries please contact Rapid Dose Therapeutics Inc at: info@rapid-dose.com.

Information in this news release may contain forward-looking information. Statements containing forward-looking information express, as at the date of this news release, the Corporation’s plans, estimates, forecasts, projections, expectations, or beliefs as to future events or results and are believed to be reasonable based on information currently available to the Corporation. There can be no assurance that forward-looking statements will prove to be accurate. Actual results and future events could differ materially

from those anticipated in such statements. Readers should not place undue reliance on forward-looking information.